RJ

Ronald Jih Wen Ling

Director Director DIN 00270513
DIN 00270513 First appointment Jul 2005 Primary industry General Business
Unlock full profile Investments Β· shareholding Β· contact details
Current companies –
Past companies 1 historical roles
Total affiliations 1 Since Jul 2005
Shareholding value β€’β€’β€’β€’ Premium profile

About Ronald Jih Wen Ling

Data last updated:

Ronald Jih Wen Ling has 21 years in corporate governance. Formerly with 1 company, such as Strides Pharma Science Limited. Engaged in General Business. Contributes to corporate operations.

DIN 00270513
Primary Designation Director
First Appointment 07 Jul 2005
Oldest Company Age –

Current companies

No current companies available.

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Strides Pharma Science Limited L24230MH1990PLC057062
Nominee Director07 Jul 20051990₹5,009 Cr (FY 2026)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Strides Pharma Science Limited
Premium access

Shareholding and investment profile for Ronald Jih Wen Ling

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ronald Jih Wen Ling

Ronald Jih Wen Ling has 21 years in corporate governance. Formerly with 1 company, such as Strides Pharma Science Limited. Engaged in General Business. Contributes to corporate operations.

Ronald Jih Wen Ling has expertise in General Business.

Ronald Jih Wen Ling has 21 years in corporate governance.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available